Does normal blood glucose (Time-in-Range) preserve insulin production in children with newly diagnosed Type 1 diabetes?
T1D is not a homogeneous disease. At onset of diagnosis, most patients still have some insulin-production left. The rate of the immune-mediated destruction of β-cells varies. Some patients lose their β-cell function soon after diagnosis; others maintain insulin production for years. Reports from several studies have shown that preservation of β-cell function results in better metabolic control, as evaluated by HbA1c, lower daily insulin-dose, reduction of long-term micro- and macro-vascular complications, and reduction of acute complications. The remaining insulin production seems to makes the blood glucose more stable and the diabetes treatment less complicated.
The remaining insulin-production in the β-cells can be measured by using C-peptide, an excellent marker for residual β-cell activity. All children with new onset T1D in 2022 in Norway will be invited to participate in this study.
Our objectives: 1) To develop a digital, user friendly, educational tool to motivate and to increase the use of Time In Range (TIR) on a daily basis in children and adolescents with new-onset T1 2) Implement this tool as a part of daily diabetes care, close to onset of T1D, and follow the children with a standardized approach the first year of T1D. 3) To show that the use of CGM and increased TIR will preserve insulin production from the onset of T1D, measured as C-peptide.
News from 2022:
The recruiting of children and adolescents started in March 2022. By the end of 2022 about 90 subjects were recruited.